2 active not recruiting, 1 terminated. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Terminated 1 |
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
Follow NP137: new trials by email Literature Review of NP137 trials Research Report on NP137
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] NP137, Azacitidine Injection, Venetoclax - Acute Myeloid Leukemia Refractory | Phase 1 / Phase 2 | Terminated | Centre Leon Berard | 1 | 2024-09-11 | 2025-02-20 |
| NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies NP137, anti-PD-1/PD-L1 - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 2 | Active not recruiting | Centre Leon Berard | 57 | 2023-01-06 | 2026-09-25 |
| GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab NP137, Pembrolizumab, Paclitaxel - Endometrial Carcinoma, Cervix Carcinoma | Phase 1 / Phase 2 | Active not recruiting | NETRIS Pharma | 240 | 2020-12-14 | 2024-10-08 |
Endometrial Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Uterine Cervical Neoplasms (1)
Centre Leon Berard (2) · NETRIS Pharma (1)
France (3)